Montelukast tablets 10 mg for asthma and rhinitis (montelukast sodium, Singulair)

General information on Japanese Montelukast tablets 10 mg for asthma and rhinitis (montelukast sodium, Singulair)

UNAVAILABLE DUE TO LACK OF RAW MATERIALS

Package details: 28 tablets

Manufacturer: Kyorin Rimedio Co., Ltd., Japan

Active ingredient: montelukast sodium (chemical formula C35H35ClNNaO3S)

Medical effect: Montelukast tablets are effective for the treatment of asthma and allergic rhinitis.

Contraindications and precautions: do not use for pregnant and breastfeeding women. If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Montelukast tablets 10 mg from Japan for asthma and rhinitis (montelukast sodium, Singulair)

For bronchial asthma: For adults, take 1 tablet (10 mg of active ingredient) at a time, once a day at bedtime.

For allergic rhinitis: For adults, take 0.5-1 tablet (5-10 mg of active ingredient) at a time, once a day at bedtime.

How effective are Montelukast tablets 10 mg from Japan for asthma and rhinitis (montelukast sodium, Singulair)?

Montelukast is a e leukotriene receptor antagonist. It works by suppressing the action of leukotriene D4 in the lungs, decreasing inflammation and relaxing the smooth muscle. As the result, Montelukast tablets provide the following effects:

• control the contraction of bronchi,
• prevent onset of coughs, wheezing and respiratory distress,
• control nasal ventilation resistance,
• improves symptoms of nasal obstruction, nasal discharge and sneezing.

Who should take Montelukast tablets 10 mg from Japan?

Japanese Montelukast tablets are effective for the treatment of the bronchial asthma and allergic rhinitis. It has a rapid onset, that’s why it’s supposed to be taken before bedtime, when the symptoms of asthma and rhinitis tend to worsen. Studies showed that montelukast is generally safe, has few side effects, does not inquire inhalator and effectively reduce the frequency of attacks in patients with asthma (Kam Lun Ellis Hon, Ting Fan Leung, Alexander K.C. Leung. “Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?”. Drug Design, Development and Therapy. 2014; 8: 839–850). However, this medicine is not designed to alleviate the asthma attack immediately, so the patient should use another medication if still needed.